Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
'Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continue to advance our development programs and execute our long-term growth strategy,' said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. 'With recent progress in regulatory approvals for zanidatamab in key international markets, including the U.S., Europe, and China, a much-anticipated, upcoming topline data readout for HERIZON-GEA-01 in the fourth quarter of 2025, and continued progress across our novel, wholly-owned pipeline, we believe Zymeworks is entering a significant period of opportunity for value creation. We look forward to Greg and Bob's contributions, as we focus on both enhancing value for our shareholders and bringing innovative therapies to more patients around the world.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
36 minutes ago
- Toronto Star
Titanium Reports Q2 2025 with 16.8% Logistics Revenue Increase; Further Debt Reduction Strengthens Balance Sheet
Consolidated revenue for Q2 2025 grew 3.5% year-over-year, to $119.1 million, driven by strength in the Logistics segment. Logistics revenue increased 16.8% year-over-year, fueled by 19% increase in US volume, highlighting growth of new customers and the scalability of Titanium's asset-light model. Enhanced financial flexibility with $12.4 million in debt reduction, $16.4 million cash on hand. BOLTON, Ontario, Aug. 11, 2025 (GLOBE NEWSWIRE) — Titanium Transportation Group Inc. ('Titanium' or the 'Company') (TSX:TTNM, OTCQX:TTNMF), a leading provider of transportation and logistics services throughout North America, is pleased to report its financial results for the three and six-month period ended June 30, 2025. All amounts are in Canadian currency.
Globe and Mail
36 minutes ago
- Globe and Mail
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO , Aug. 11, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows: Director For % Withheld % Patricia Andrews 10,498,328 88.83 % 1,320,714 11.17 % Deborah M. Brown 10,115,110 85.58 % 1,703,932 14.42 % Jared Kelly 10,830,605 91.64 % 988,437 8.36 % Angela Holtham 10,175,887 86.10 % 1,643,155 13.90 % James T. Parsons 10,172,958 86.07 % 1,646,084 13.93 % Wayne Pisano 10,148,894 85.87 % 1,670,148 14.13 % Jonathan Rigby 9,508,770 80.45 % 2,310,272 19.55 % Bernd R. Seizinger 10,269,441 86.89 % 1,549,601 13.11 % In addition to the election of all nominees listed as directors in the management information circular, dated June 18 , 2025, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year. For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: or follow the Company on social media on LinkedIn and on X @ oncolytics. Company Contact Jon Patton Director of IR & Communication jpatton@ Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@ Media Contact for Oncolytics Owen Blaschak LifeSci Communications oblaschak@ Logo - SOURCE Oncolytics Biotech® Inc.
Toronto Star
an hour ago
- Toronto Star
Westport Reports Second Quarter 2025 Financial Results
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. ('Westport') (TSX:WPRT / Nasdaq:WPRT), a supplier of alternative fuel systems and components for the global transportation industry, reported financial results for the second quarter ended June 30, 2025, and provided an update on operations. All figures are in U.S. dollars unless otherwise stated. 'We made significant progress in advancing our strategic transformation this quarter, culminating in the recent successful divestiture of our Light-Duty Segment on July 29, 2025. This transaction strengthens our balance sheet and sharpens our strategic focus on high-impact opportunities in commercial transportation and industrial applications — sectors with few alternatives to affordably decarbonize and where Westport is uniquely positioned to provide affordable solutions that create the greatest potential for long-term growth. Beyond reinforcing our financial position, the divestiture provides us with greater flexibility to invest in innovation and evaluate select strategic acquisitions that can enhance our capabilities or expand our presence in prioritized markets.
